AR102767A1 - Inhibidores de ezh2 - Google Patents

Inhibidores de ezh2

Info

Publication number
AR102767A1
AR102767A1 ARP150103834A ARP150103834A AR102767A1 AR 102767 A1 AR102767 A1 AR 102767A1 AR P150103834 A ARP150103834 A AR P150103834A AR P150103834 A ARP150103834 A AR P150103834A AR 102767 A1 AR102767 A1 AR 102767A1
Authority
AR
Argentina
Prior art keywords
ezh2 inhibitors
dihydropyridin
methylthiophene
carboxamide
oxo
Prior art date
Application number
ARP150103834A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of AR102767A1 publication Critical patent/AR102767A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado porque se selecciona a partir del grupo que consiste de: N-[(4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil]-5-{(1R)-1-[trans-4-(3-metoxiazetidin-1-il)ciclohexil]etil}-4-metiltiofen-3-carboxamida de fórmula (1), o una sal del mismo farmacéuticamente aceptable, y N-[(4,6-dimetil-2-oxo-1,2-dihidropiridin-3-il)metil]-5-{(1S)-1-[trans-4-(3-metoxiazetin-1-il)ciclohexil]etil}-4-metiltiofen-3-carboxamida de fórmula (2), o una sal del mismo farmacéuticamente aceptable.
ARP150103834A 2014-12-05 2015-11-24 Inhibidores de ezh2 AR102767A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462088045P 2014-12-05 2014-12-05

Publications (1)

Publication Number Publication Date
AR102767A1 true AR102767A1 (es) 2017-03-22

Family

ID=55025363

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150103834A AR102767A1 (es) 2014-12-05 2015-11-24 Inhibidores de ezh2

Country Status (4)

Country Link
US (1) US9527837B2 (es)
AR (1) AR102767A1 (es)
TW (1) TW201636344A (es)
WO (1) WO2016089804A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ｅｚｈ２抑制劑
CN109328188A (zh) 2016-05-05 2019-02-12 葛兰素史密斯克莱知识产权（第2 号）有限公司 Zeste增强子同源物2抑制剂
US11311524B2 (en) 2017-01-19 2022-04-26 Daiichi Sankyo Company, Limited Pharmaceutical composition used for treatment of HTLV-1-associated myelopathy
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
CA3089639C (en) 2018-01-31 2024-06-18 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidinyl compounds as prc2 inhibitors
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CA3148444A1 (en) * 2019-07-24 2021-01-28 Constellation Pharmaceuticals, Inc. Ezh2 inhibition therapies for the treatment of cancers
CN110960525A (zh) * 2019-11-26 2020-04-07 济南大学 新型eed-ezh2相互作用抑制剂的确定和评价
TW202400140A (zh) 2022-04-27 2024-01-01 日商第一三共股份有限公司 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521794A (ja) 2003-02-14 2006-09-28 スミスクライン・ビーチャム・コーポレイション Ｋｓｐ発現と相関関係にある示差発現核酸
WO2011140325A1 (en) 2010-05-07 2011-11-10 Glaxosmithkline Llc Indazoles
US8637509B2 (en) 2010-05-07 2014-01-28 Glaxosmithkline Llc Azaindazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
RU2765155C2 (ru) 2010-09-10 2022-01-26 Эпизайм, Инк. Ингибиторы ezh2 человека и способы их применения
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
WO2012068589A2 (en) 2010-11-19 2012-05-24 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
US8765792B2 (en) 2010-12-01 2014-07-01 Glaxosmithkline Llc Indoles
AU2012223448B2 (en) 2011-02-28 2017-03-16 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
TWI598336B (zh) 2011-04-13 2017-09-11 雅酶股份有限公司 經取代之苯化合物
JO3438B1 (ar) 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
US9073924B2 (en) 2011-09-13 2015-07-07 Glaxosmithkline Llc Azaindazoles
EP2760452A4 (en) 2011-09-30 2015-04-01 Glaxosmithkline Llc METHODS OF TREATING CANCER
WO2013067302A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
AU2012332297B2 (en) 2011-11-04 2016-01-07 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
WO2013067300A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No. 2) Limited Method of treatment
US9206128B2 (en) 2011-11-18 2015-12-08 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
JP6340361B2 (ja) 2012-04-13 2018-06-06 エピザイム，インコーポレイティド がんを処置するための組合せ治療
KR20220123339A (ko) 2012-04-13 2022-09-06 에피자임, 인코포레이티드 인간 히스톤 메틸트랜스퍼라제 ｅｚｈ２ 억제제의 염 형태
WO2013173441A2 (en) 2012-05-16 2013-11-21 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
EP2900653A1 (en) 2012-09-28 2015-08-05 Pfizer Inc. Benzamide and heterobenzamide compounds
NZ746054A (en) 2012-10-15 2020-07-31 Epizyme Inc Methods of treating cancer
EP2931707A4 (en) 2012-12-13 2016-07-20 Glaxosmithkline Llc AMPLIFIER OF ZEST HOMOLOG 2 INHIBITORS
US20150313906A1 (en) 2012-12-19 2015-11-05 Glaxosmithkline Llc Combination
WO2014100646A1 (en) 2012-12-21 2014-06-26 Epizyme, Inc. 1,4-pyridone compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
US9701666B2 (en) 2012-12-21 2017-07-11 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
EA030196B1 (ru) 2013-04-30 2018-07-31 Глэксосмитклайн Интеллекчуал Проперти (No.2) Лимитед Ингибиторы энхансера zeste гомолога 2
RU2016104044A (ru) 2013-07-10 2017-08-15 Глэксосмитклайн Интеллекчуал Проперти (Nо.2) Лимитед Ингибиторы усилителя zeste гомолога 2
US9738630B2 (en) 2013-11-19 2017-08-22 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015077194A1 (en) 2013-11-22 2015-05-28 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
WO2015104677A1 (en) 2014-01-10 2015-07-16 Piramal Enterprises Limited Heterocyclic compounds as ezh2 inhibitors
MX2021007651A (es) 2014-06-17 2021-08-11 Epizyme Inc Inhibidores de ezh2 para tratar linfomas.

Also Published As

Publication number Publication date
TW201636344A (zh) 2016-10-16
WO2016089804A1 (en) 2016-06-09
US9527837B2 (en) 2016-12-27
US20160159782A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
AR102767A1 (es) Inhibidores de ezh2
EA201790398A1 (ru) Способы лечения заболевания печени
AR110381A2 (es) Inhibidores biarilo de tirosina cinasa de bruton
AR108711A1 (es) Compuestos moduladores de fxr (nr1h4)
ZA201701299B (en) Glycosidase inhibitors
AR103680A1 (es) Inhibidores selectivos de bace1
EA201691579A1 (ru) Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
SG11201900868XA (en) Ido1 inhibitor and preparation method and application thereof
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
UY36151A (es) ?una composición farmacéutica que comprende un inhibidor de fosfoinosítido 3-quinasa delta y un corticosteroide?.
PH12016502062A1 (en) Compositions and methods for modulating completent factor b expression
EA201692480A1 (ru) Фармацевтическая композиция
EA201891342A1 (ru) Изоиндольные соединения
MY194106A (en) Dihydroindolizinone derivative
MX2016011105A (es) Inhibidores de monoacilglicerol aciltransferasa 2 (mgat2) de dihidropiridinona para usarse en el tratamiento de trastornos metabolicos.
EA201891440A1 (ru) Составы/композиции, содержащие ингибитор btk
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
AR104342A1 (es) Compuesto heterocíclico
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
WO2016094834A3 (en) A method for treating a complement mediated disorder caused by an infectious agent in a patient
SV2016005313A (es) Derivados de carboxamida
JOP20190163B1 (ar) منشط nrf2
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
EA201500941A1 (ru) Способы и композиции для модуляции гамма-глутамилового цикла

Legal Events

Date Code Title Description
FB Suspension of granting procedure